Premium
Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia
Author(s) -
Hunger Stephen P.,
Loh Mig L.,
Whitlock James A.,
Winick Naomi J.,
Carroll William L.,
Devidas Meenakshi,
Raetz Elizabeth A.
Publication year - 2013
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24420
Subject(s) - medicine , lymphoblastic leukemia , oncology , pediatric oncology , blood cancer , risk stratification , chemotherapy , blueprint , white blood cell , leukemia , clinical trial , pediatrics , cancer , mechanical engineering , engineering
Approximately 90% of the 2,000 children, adolescents, and young adults enrolled each year in Children's Oncology Group acute lymphoblastic leukemia (ALL) trials will be cured. However, high‐risk subsets with significantly inferior survival remain, including infants, newly diagnosed patients with age ≥10 years, white blood count ≥50,000/µl, poor early response or T‐cell ALL, and relapsed ALL patients. Effective strategies to improve survival include better risk stratification, optimizing standard chemotherapy and combining targeted therapies with cytotoxic chemotherapy, the latter of which is dependent upon identification of key driver mutations present in ALL. Pediatr Blood Cancer 2013; 60: 957–963. © 2012 Wiley Periodicals, Inc.